The approval was based on data from the randomized, double-blind, placebo-controlled, phase 3 CheckMate -77T trial.

The checkpoint inhibitor is now approved, based on CheckMate 77T findings, for neoadjuvant/adjuvant use in patients with resectable NSCLC.

The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...

No benefit seen for rechallenge with nivolumab after progression in the post-immune checkpoint inhibitor setting.

When cancer cells mutate, they produce small peptides called neoantigens.  Because neoantigens remain relatively unique to ...

Two strategies to de-escalate treatment for human papillomavirus (HPV)-positive oropharyngeal cancer failed to show ...

An expert explains study findings that associate a longer time until postsurgical melanoma recurrence with improved ...

The Phase 2b HBV003 trial (NCT05343481) has enrolled 121 participants and is designed to obtain critical dosing information for a potential functional cure regimen for CHB, with participants receiving ...

In it, they give the example of a cancer drug called nivolumab, which can improve outcomes for patients. In trials – during which people with different 'types' of cancer were included – the drug has ...

The NRG Oncology NRG-HN005 phase II/III clinical trial has not met the non-inferiority criteria to proceed to the phase III ...

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...

By blocking this protein, cetuximab stops the cancer cells from growing. Pembrolizumab and nivolumab are immunotherapy drugs called PD-1 inhibitors. They target and block a checkpoint protein called ...